Document is current

Article History

Accepted: 7 November 2025

First Online: 27 November 2025

Competing interests

: F.P. has received grants and personal fees from Novartis, Eli Lilly and UCB and personal fees from AbbVie, AMGEN, BMS, Celgene, Janssen, Hexal, Medscape, Moonlake, MSD, Pfizer and Roche outside the presented work. A.L.R. has received honoraria and support for attending conferences from Novartis, Eli Lilly, UCB, AbbVie and Janssen, all outside the presented work. S.S. has received consulting fees from AbbVie, Johnson & Johnson and UCB, speaker fees from Johnson & Johnson, and research grants from AbbVie, Eli Lilly and Prometheus Biosciences. V.C. has received grants from AbbVie, Amgen and Eli Lilly and honoraria for advisory board member roles from AbbVie, BMS, Eli Lilly, Fresenius Kabi, Janssen, Novartis and UCB; V.C.’s spouse is an employee of AstraZeneca; and V.C. is supported by the Dr. Dafna D. Gladman Chair in Psoriatic Arthritis Research, a joint Hospital-University Named Chair between the University of Toronto, the University Health Network, and the UHN Foundation. W.L. has received research funding from Amgen, Janssen, Leo and Regeneron. C.L. has acted as a consultant for Tonix Pharmaceuticals, and owns stock with Amgen and Arcutis. E.R.S. has participated in advisory boards for, given conferences for and/or received grants from AbbVie, Amgen, Bristol-Myers Squibb, Elea, Glaxo, Janssen, Lilly, Montpellier, Novartis, Pfizer, Raffo, Roche, Sandoz and UCB. T.B. has received research funding from Amgen, Castle, CorEvitas, Novartis, Pfizer and Regeneron; she has served as an adviser for AbbVie, Arcutis, Aslan, Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Pfizer, Novartis, Sanofi, Sun, Takeda and UCB; and she is a speaker for AbbVie, Amgen, Arcutis, BMS, Dermavant, Galderma, Janssen, Lilly, Leo, Ortho, Sanofi and UCB. A.D. has participated in consulting and advisory boards for Bristol Myers Squibb, Eli Lilly, J&J, Novartis, Pfizer, UCB, and has received research grants from Bristol Myers Squibb, Eli Lilly, J&J, MoonLake, Novartis, Pfizer and UCB. K.d.V. has participated in consulting and advisory boards for Bristol Myers Squibb, Eli Lilly, J&J, Novartis, Pfizer, UCB, AlfaSigma, Moonlake & Allegro, and has received research grants from Pfizer and UCB. L.E. has received grants from AbbVie, UCB, Novartis, J&J, Eli Lilly, Pfizer, Novo Nordisk, Fresenius Kabi and Amgen, and has participated in consulting for BMS, AbbVie, UCB, Novartis, J&J and Eli Lilly. M.K. has received speakers bureau fees from AbbVie, Amgen, Asahi-Kasei Pharma, Ayumi Pharma, BMS, Chugai, Daiichi Sankyo, Eisai, Janssen, Lilly, Novartis, Tanabe-Mitsubishi and UCB, and has acted as a consultant for AbbVie, Amgen, Asahi-Kasei Pharma, Ayumi Pharma, BMS, Chugai, Gilead, Janssen, Lilly, Novartis, Takeda, Tanabe-Mitsubishi and UCB. Y.Y.L. has received speaking fees from AbbVie, DKSH, Jassen, Novartis and Pfizer, outside of the present work. E.L. has received speaker´s fees from AbbVie, Lilly, Janssen, Novartis and UCB. D.M. has received grants and speaker fees from AbbVie, BMS, Novartis, Eli Lilly, UCB, Celgene, Janssen, Moonlake and Pfizer. D.P. has received research grants from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB, consulting fees from AbbVie, Eli Lilly, Greywolf Therapeutics, Janssen, Merk, Moonlake, Novartis, Pfizer and UCB, and speaker fees from AbbVie, Canon, Eli Lilly, Janssen, Medscape, Novartis, Peervoice, Pfizer and UCB; he serves as a member of the executive committee of ASAS, a member of the steering committee of GRAPPA, and editor of Therapeutic Advances in Musculoskeletal Disease . L.S. has received honoraria from AbbVie, Almirall, Novartis, Janssen, Lilly, UCB, Pfizer, Bristol-Myers-Squibb, Boehringer Ingelheim, Amgen, Medac, Moonlake, Leo Pharma, Takeda, Galderma, Biogen, Celgene, Celltrion, Sanofi and Fresenius Kabi for consulting and speaker roles, and has received support for travel from AbbVie, Janssen, Lilly, Novartis, UCB, Bristol-Myers-Squibb, Boehringer Ingelheim and Leo Pharma. F.V.d.B. has received consulting fees from AbbVie, Alfasigma, Celltrion, Eli Lilly, Fresenius Kabi, GreyWolf Therapeutics, Janssen, Novartis, UCB and Xencor. P.M. has received research grants, consulting fees and speaker fees from AbbVie, Acelyrin, Amgen, Bristol Meyers Squibb, Century, Eli Lilly, Inmagene, Johnson & Johnson, Moonlake, Novartis, Pfizer, Takeda and UCB, and is a data safety board member of Genascence.

Free to read: This content has been made available to all.